SCHEMBL4870655

SCHEMBL4870655

FC(F)(F)c1cc(Br)c(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.51
SLC6A4 P31645 1/20 0.51
HTR2B P41595 1/20 0.51
PTPN1 P18031 6/20 0.50
PTPN6 P29350 3/20 0.50
PTPN2 P17706 2/20 0.50
THRB P10828 3/20 0.49
THRA P10827 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
MAPT P10636 4/20 0.44
GAA P10253 3/20 0.44
TP53 P04637 1/20 0.44
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HPGD P15428 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15729804 0.85 THRA (0.49) HTR2CSLC6A4HTR2BPTPN1PTPN6
SCHEMBL30821972 0.82 SLC6A4 (0.56) HTR2CSLC6A4HTR2BPTPN1PTPN6
SCHEMBL17305160 0.82 HTR2C (0.56) HTR2CSLC6A4HTR2BPTPN1PTPN6
SCHEMBL1332170 0.82 SLC6A4 (0.56) HTR2CSLC6A4HTR2BPTPN1PTPN6
Benzyl Bromide SCHEMBL5984626 0.77 SLC6A4 (0.52) HTR2CSLC6A4HTR2BPTPN1PTPN6
SCHEMBL12370682 0.75 THRB (0.54) THRBTHRASMN1; SMN2MAPTGAA
SCHEMBL4870023 0.75 LMNA (0.52) PTPN1PTPN6PTPN2RXRARXRB
SCHEMBL2893555 0.75 MAPK14 (0.43) HTR2CSLC6A4HTR2BPTPN1PTPN6
SCHEMBL8924430 0.74 MAOB (0.53) SLC6A4THRBTHRASMN1; SMN2MAPT
SCHEMBL1333232 0.74 HTR2C (0.58) HTR2CSLC6A4HTR2BPTPN1PTPN6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 HTR2C 55/4885SLC6A4 119/4885HTR2B 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.